Superloop Limited's Paul Tyler speaks with Proactive during the ASX Small and Mid-Cap Conference, March 2022.

The company's purpose is to enable better internet for Australian homes and businesses by allowing challenger retail brands - including its own Superloop and Exetel brands - to take a larger share of the market, leveraging Superloop's Infrastructure-on-Demand platform.

Peter Warren Automotive's Mark Weaver speaks with Proactive during the ASX Small and Mid-Cap Conference, March 2022.

The company's an automotive dealership group that's been operating in Australia for over 60 years. It operates 82 franchise operations and represents 28 OEMs.

SILK Laser Australia's Martin Perelman speaks with Proactive during the ASX Small and Mid-Cap Conference, March 2022.

SILK is one of Australia’s largest specialist clinic networks, offering a range of nonsurgical aesthetic products and services. Its five core offerings comprise laser hair removal, cosmetic injectables, skin treatments, body contouring and skincare products.

Atomo Diagnostics Ltd's John Kelly speaks with Proactive during the ASX Small and Mid-Cap Conference. It's an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Next Science Limited's Judith Mitchell speaks with Proactive during the ASX Small and Mid-Cap Conference. The company's primary focus is on the development and continued commercialisation of its proprietary XBIO technology to reduce the impact of biofilm based infections in human health.

EBR Systems' John McCutcheon speaks with Proactive during the ASX Small and Mid-Cap Conference. The company's focused on the treatment of cardiac rhythm disease by providing more

physiologically effective stimulation through wireless cardiac pacing. Its Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads.

Race Oncology Ltd's Phillip Lynch speaks with Proactive during the ASX Small and Mid-Cap Conference. They're a precision oncology company with a cancer drug called Zantrene®. It's a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers.

Opthea Limited's Megan Baldwin speaks with Proactive during the ASX Small and Mid-Cap Conference, March 2022.

It's a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases.

Monash IVF Group's Michael Knaap speaks with Proactive during the ASX Small and Mid-Cap Conference. The company's a provider of assisted reproductive services and specialist women’s imaging and diagnostic services in Australia and South East Asia.

Genex Power's Simon Kidston speaks with Proactive during the ASX Small and Mid-Cap Conference, March 2022. The company has a portfolio of more than $1 billion of renewable energy generation and storage projects across Australia. Its flagship Kidston Clean Energy Hub, located in north

Queensland, will integrate large-scale solar generation with pumped storage hydro.